RISING DRUG COSTS WITH STABLE 12-MONTH SURVIVAL IN INCIDENT METASTATIC BREAST CANCER IN GERMANY, 2011-2024
Author(s)
Benjamin Birkner, Dr.1, Antje Mevius, MA2, Barthold Deiters, Dr.3, Sabrina Müller, MSc4, Stefano Tagliabue, MSc4, Thomas Wilke, PhD2.
1GWQ ServicePlus AG, Hamburg, Germany, 2IPAM e.V., Wismar, Germany, 3GWQ ServicePlus AG, Düsseldorf, Germany, 4GIPAM GmbH, Wismar, Germany.
1GWQ ServicePlus AG, Hamburg, Germany, 2IPAM e.V., Wismar, Germany, 3GWQ ServicePlus AG, Düsseldorf, Germany, 4GIPAM GmbH, Wismar, Germany.
OBJECTIVES: To describe trends in age- and sex-standardized 12-month overall survival (OS) and inflation-adjusted costs among patients with incident metastatic breast cancer (mBC) in anonymized German statutory health insurance claims data from 2011 to 2024.
METHODS: Patients with mBC were identified using ICD-10-GM diagnosis codes: C50 (BC) and C77-C79 for metastatic disease. Metastatic disease was required to occur within ±3 months of the qualifying BC diagnosis, with no evidence of mBC during a 1-year baseline period. Age- and sex-standardized 12-month OS, standardized to the overall German statutory health insurance population, was assessed from the date of incident mBC (index date). Fourteen annual cohorts were defined according to index date year of each patient (2011-2024). Inflation-adjusted all-cause healthcare costs were measured over the 12-month post-index period for each patient and reported by index-year cohort. Trends in OS and costs were evaluated over time, using 2011 as the reference year.
RESULTS: In each of the 14 observed years, between 353 and 1,127 patients were observed; >97% were female, and mean age increased from 60.0 to 62.7 years over the years. Standardized 12-month OS decreased from 93.3% in 2011 to 86.4% in 2016, and then was higher than 89% in each of the subsequent years. Highest OS was observed for index years 2020 and 2024 (93.9%). Costs increased steadily between 2011 and 2024 from €31,771 to €39,033 per patient (+22.9%). Costs excluding the final 4 weeks before death increased from €31,095 to €38,177. The cost increase was mainly driven by outpatient drug costs, which rose from €14,821 to €19,385 per patient. Compared to 2011 (index=100), OS did not change (index 2024: 100.6%), whereas all-cause costs increased by 22.9% compared to the 2011 value.
CONCLUSIONS: In incident mBC, standardized 12-month OS remained broadly stable over the last 14 years while treatment costs increased steadily.
METHODS: Patients with mBC were identified using ICD-10-GM diagnosis codes: C50 (BC) and C77-C79 for metastatic disease. Metastatic disease was required to occur within ±3 months of the qualifying BC diagnosis, with no evidence of mBC during a 1-year baseline period. Age- and sex-standardized 12-month OS, standardized to the overall German statutory health insurance population, was assessed from the date of incident mBC (index date). Fourteen annual cohorts were defined according to index date year of each patient (2011-2024). Inflation-adjusted all-cause healthcare costs were measured over the 12-month post-index period for each patient and reported by index-year cohort. Trends in OS and costs were evaluated over time, using 2011 as the reference year.
RESULTS: In each of the 14 observed years, between 353 and 1,127 patients were observed; >97% were female, and mean age increased from 60.0 to 62.7 years over the years. Standardized 12-month OS decreased from 93.3% in 2011 to 86.4% in 2016, and then was higher than 89% in each of the subsequent years. Highest OS was observed for index years 2020 and 2024 (93.9%). Costs increased steadily between 2011 and 2024 from €31,771 to €39,033 per patient (+22.9%). Costs excluding the final 4 weeks before death increased from €31,095 to €38,177. The cost increase was mainly driven by outpatient drug costs, which rose from €14,821 to €19,385 per patient. Compared to 2011 (index=100), OS did not change (index 2024: 100.6%), whereas all-cause costs increased by 22.9% compared to the 2011 value.
CONCLUSIONS: In incident mBC, standardized 12-month OS remained broadly stable over the last 14 years while treatment costs increased steadily.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE397
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology